2,130
+1.87%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fuso Pharmaceutical Industries
Its shares trade on Tokyo Stock Exchange under the ticker 4538.T. It has been listed since 22 December 1989. In the fiscal year to 31 March 2026, it reported revenue of ¥62.31bn and net income of ¥2.01bn. At that date it held total assets of ¥90.32bn and shareholders' equity of ¥35.06bn.
Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. The company is headquartered in Osaka, Osaka-Fu. The firm operates in two business segments. The Pharmaceuticals segment is involved in manufacture and sale of pharmaceutical products, including injectable drugs, which mainly focus on infusion solution, dialysis fluid for artificial kidney, as well as the manufacture and sale of medical equipment and instruments. The Real Estate segment is engaged in the leasing of real estate properties.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Dec 1989
- Employees
- 1,314
- Website
- fuso-pharm.co.jp ↗
Leadership
Pay as last reported
- Mr. Mikio TodaPresident, Representative Director, since 1969
- Mr. Hideki OtaniChief Director of Sales, Director, since 2017
- Mr. Kiyoshi TajimaExecutive Officer, Manager of Tokyo 1st Office in Main Sales Office Unit, Manager of Tokyo Business Center
- Mr. Haruhiko FuruichiExecutive Officer, Director of General Affairs, Director of Accounting
- Mr. Mamoru MiyakeExecutive Officer, Manager of Research and Development Center
- Mr. Syoukichi NishimuraExecutive Officer, Manager of Internal Audit Office, since 2005
- Ms. Taeko OkadaExecutive Officer, Director of Production Administration in Main Production Unit
- Mr. Michikazu SaitoExecutive Officer, Manager of Osaka Office in Main Sales Unit
- Mr. Junji ShiomiExecutive Officer
- Mr. Satoshi TanakaExecutive Officer, Chief Director of Reliability Guarantee
- Mr. Mitsuro UotaniExecutive Officer, Director of Distribution Promotion in Main Sales Unit
- Mr. Hirohumi YamamotoExecutive Officer, Okayama Plant Manager in Main Production Unit
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fuso Pharmaceutical Industries employs 1,314 full-time employees in Osaka, Japan.
- The Pharmaceuticals segment focuses on infusion solutions and dialysis fluids for medical use.
- The Real Estate segment provides stable leasing income from property assets.
Weaknesses
- The company's business is limited to two segments with no diversification into other industries.
- The Real Estate segment's income is dependent on property leasing market conditions.
- Pharmaceutical manufacturing requires significant regulatory compliance and quality control.
Opportunities
- Growing demand for dialysis fluids in Japan's aging population.
- Expansion of pharmaceutical sales in the Japanese healthcare market.
- Potential for real estate leasing in Osaka's commercial districts.
Threats
- Regulatory changes in Japan's pharmaceutical industry could increase compliance costs.
- Economic downturns may reduce demand for non-essential medical equipment.
- Competition from larger pharmaceutical firms in Japan's market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.